Clinical Trial Update: Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating glumetinib with osimertinib for relapsed/refractory non-small cell lung cancer after EGFR inhibitor failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Glumetinib
• Osimertinib (osimertinib)

Snippet

Sponsor: Haihe Biopharma Co., Ltd. | Conditions: Negative T790M Mutation and Met Amplification | Phase 1, Phase 2 | Status: UNKNOWN